Title |
A cross-sectional study of the effects of β-blocker therapy on the interpretation of the aldosterone/renin ratio
|
---|---|
Published in |
Journal of Hypertension, February 2016
|
DOI | 10.1097/hjh.0000000000000775 |
Pubmed ID | |
Authors |
Tomás P. Griffin, Gerard A. Browne, Deirdre Wall, Michael C. Dennedy, Paula M. OʼShea |
Abstract |
Aldosterone/renin ratio (ARR) is used as the primary screening tool for primary aldosteronism. Its interpretation is often challenging because of the interference of antihypertensive medication. β-blocker therapy suppresses renin production by inhibiting β-adrenergic receptors in the juxtaglomerular apparatus of the kidney and consequently aldosterone secretion (to a lesser extent). Therefore, β-blocker therapy has the potential to elevate the ARR. The aim of this study was to investigate whether or not the effect of β-blocker therapy on the ARR could be predicted from the dosing regimen. A prospective cross-sectional study was conducted. Participants were stratified into one of four groups (control/low/medium/high) based on the quantity of β-blocker prescribed. ARR was calculated from renin/aldosterone, measured using two assay systems. Eighty-nine volunteers were recruited to our study. In the control group, zero patients had a positive ARR using plasma renin activity (PRA)/direct renin concentration (DRC). In the low, medium, and high-dose β-blocker groups between 8-25% of patients demonstrated screen positive ARR results for primary aldosteronism using DRC and PRA. DRC was significantly lower in patients in the medium/high-dose groups and PRA significantly lower in the low/medium/high-dose groups compared with controls. ARR using DRC was significantly higher in the medium/high-dose groups and ARR using PRA was significantly higher in the low/medium/high-dose groups compared with controls. Our study suggests that β-blocker therapy is associated with an increased risk of positive ARR screens for primary aldosteronism irrespective of the dose of β-blocker prescribed, in patients in whom it is clinically reasonable to expect that primary aldosteronism may be present. |
Twitter Demographics
Geographical breakdown
Country | Count | As % |
---|---|---|
Unknown | 1 | 100% |
Demographic breakdown
Type | Count | As % |
---|---|---|
Science communicators (journalists, bloggers, editors) | 1 | 100% |
Mendeley readers
Geographical breakdown
Country | Count | As % |
---|---|---|
Unknown | 17 | 100% |
Demographic breakdown
Readers by professional status | Count | As % |
---|---|---|
Student > Postgraduate | 4 | 24% |
Other | 3 | 18% |
Student > Ph. D. Student | 2 | 12% |
Researcher | 2 | 12% |
Student > Master | 2 | 12% |
Other | 0 | 0% |
Unknown | 4 | 24% |
Readers by discipline | Count | As % |
---|---|---|
Medicine and Dentistry | 7 | 41% |
Biochemistry, Genetics and Molecular Biology | 2 | 12% |
Pharmacology, Toxicology and Pharmaceutical Science | 1 | 6% |
Unspecified | 1 | 6% |
Unknown | 6 | 35% |